Test second Paxlovid course in patients with COVID rebound: USFDA asks Pfizer
Bengaluru: The U.S. Food and Drug Administration (USFDA) has asked Pfizer Inc to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.The drugmaker must produce the initial results of a randomized controlled trial of a second course of the antiviral by Sep. 30 next year, the FDA...
Login or Register to read the full article
Bengaluru: The U.S. Food and Drug Administration (USFDA) has asked Pfizer Inc to test the effects of an additional course of its antiviral Paxlovid among people who experience a rebound in COVID-19 after treatment, the regulator said on Friday.
The drugmaker must produce the initial results of a randomized controlled trial of a second course of the antiviral by Sep. 30 next year, the FDA told Pfizer in a letter dated Aug. 5.
The directive follows reports of recurrent viral infection or symptoms, or both, after the first course, including in President Joe Biden and National Institute of Allergy and Infectious Diseases Director Dr. Anthony Fauci.
The incidents, which Pfizer says are rare, prompted the FDA to start talks with the company about the trial in May.
The regulator said a protocol for the study is expected to be finalized this month.
Pfizer is "working with the FDA to finalize a protocol to study patients who may be in need of retreatment" and will provide details when available, a company spokesperson said.
Read also: Pfizer COVID booster gets Canadian nod for kids 5-11
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd